OMER News and Press, Omeros Corporation From 04/03/19

-- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- Omeros Corporation (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of gastrointestinal hematopoietic ...

--Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation t...

Omeros ( OMER ) is a clinical stage biotech that is in the midst of a pullback. I expect it to recover and will be watching for healthy returns once one of its Phase 3 candidates hauls in an FDA or EMA approval. In the meantime, Omeros presents a highly attractive speculative acquisition as I ...

Love is like war: easy to begin but very hard to stop ." - H. L. Mencken Omeros ( OMER ) has one of the biggest love/hate followings in the biotech sector. There are bulls who believe that if its primary drug candidate OMS721 is approved for any one or possibly two indications of the fi...

Omeros Corporation (OMER) Q4 2018 Results Earnings Conference Call March 01, 2019 08:30 AM ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Chairman and Chief Executive Officer Michael Jacobsen - Chief Accounting Officer Conference Call Part...

Puma Biotechnology (NYSE: PBYI ) +30%  on Q4 earnings . More news on: Puma Biotechnology, Inc., Funko, Inc., The Gap, Inc., Stocks on the move, Read more ...

Omeros ( OMER ) Q4 results : Revenues: $22M (+59.4%). More news on: Omeros Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Omeros (NASDAQ: OMER ): Q4 GAAP EPS of -$0.48 beats by $0.26 . More news on: Omeros Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

– Conference Call Today at 8:30 a.m. ET – Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targe...

Omeros Corporation (OMER) has been a real puzzle for years. Some years ago, when its drug Omidria's pass-through status was about to be rescinded, we wrote positively about the stock, saying, one, that they will get back pass-through status, and two, OMS721 is the key (read our previous cover...